ArticleInternational journal of cancer2016
Tobacco carcinogen induces both lung cancer and non-alcoholic steatohepatitis and hepatocellular carcinomas in ferrets which can be attenuated by lycopene supplementation.
Article in International journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies.Nutrients · 2022Pooled it
- Aflatoxins as a risk factor for liver cirrhosis: a systematic review and meta-analysis.BMC pharmacology & toxicology · 2020Pooled it
- Anti-Cancer Effects of Lycopene in Animal Models of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2020Pooled it
- Antioxidants in Oxidative Stress and Obesity-Associated Diseases: Molecular Mechanisms and Potential Health Implications.Biomedicines · 2026Review
- Structure-guided design and DFT-based optimization of natural product-derived dual inhibitors targeting CDK-1 and PARP-1.Molecular diversity · 2026Article
- Lycopene, Carotenoids, and Retinoids in Cancer Chemoprevention: Molecular Mechanisms and Clinical Implications.Nutrients · 2026Review
- Guineenoside B a triterpenoid saponin from Piper guineense (Piperaceae) triggers apoptosis and PI3K/Akt/mTOR inactivation and inhibits metastasis.BMC complementary medicine and therapies · 2026Article
- Arjunolic Acid From Terminalia ivorensis A. Chev (Combretaceae) Possesses Anti-Breast Cancer Effects In Vitro and In Vivo.Cancer reports (Hoboken, N.J.) · 2025Article
- Natural Metabolites as Modulators of Sensing and Signaling Mechanisms: Unlocking Anti-Ovarian Cancer Potential.Biomedicines · 2025Review
- Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy.Cells · 2025Review
- Therapeutic Targeting of PARP Expression and Glycolysis Rate-Limiting Enzymes in Breast Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Incredible use of plant-derived bioactives as anticancer agents.RSC advances · 2025Review
- Screening and validating the optimal panel of housekeeping genes for 4T1 breast carcinoma and metastasis studies in mice.Scientific reports · 2024Article
- Physicochemical properties, mechanism of action of lycopene and its application in poultry and ruminant production.Frontiers in veterinary science · 2024Review
- Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease.Molecules (Basel, Switzerland) · 2023Review
- Article
- Antioxidant Compounds from Edible Mushrooms as Potential Candidates for Treating Age-Related Neurodegenerative Diseases.Nutrients · 2023Review
- Dietary Phytochemicals as Potential Chemopreventive Agents against Tobacco-Induced Lung Carcinogenesis.Nutrients · 2023Review
- Dietary Antioxidants and Lung Cancer Risk in Smokers and Non-Smokers.Healthcare (Basel, Switzerland) · 2022Review
- Tracking the Development of Cancer Care After 75 Years of Independence: India's Fight Against Cancer Since 1947.Indian journal of surgical oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Early epidemiologic studies have reported that tobacco smoking, which is causally associated with liver cancer, is an independent risk factor for non-alcoholic fatty liver diseases (NAFLD). Lycopene from tomatoes has been shown to be a potential preventive agent against NAFLD and hepatocellular carcinoma (HCC). In the present study, we investigated whether the tobacco carcinogen 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces lesions in both lungs and livers of ferrets with or without lycopene intervention. Male ferrets (6 groups, n = 8-10) were treated either with NNK (50 mg/kg BW, i.p., once a month for four consecutive months) or saline with or without dietary lycopene supplementation (2.2 and 6.6 mg/kg BW/day, respectively) for 26 weeks. Results demonstrate that NNK exposure results in higher incidences of lung tumors, HCC and steatohepatitis (which is characterized by severe inflammatory cell infiltration with concurrent fat accumulation in liver, hepatocellular ballooning degeneration and increased NF-κB expression), as well as elevations in bilirubin and AST levels in ferrets. Lycopene supplementation at two doses prevented NNK-induced expressions of α7 nicotinic acetylcholine receptor in the lung and NF-κB and CYP2E1 in the liver and attenuated the NNK-induced mortality and pathological lesions in both the lungs and livers of ferrets. The present study provided strong experimental evidence that the tobacco carcinogen NNK can induce both HCC and steatohepatitis in the ferrets and can be a useful model for studying tobacco carcinogen-associated NAFLD and liver cancer. Furthermore, lycopene could provide potential benefits against smoke carcinogen-induced pulmonary and hepatic injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.